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1. ABSTRACT 
The present study aimed to develop a immediate release of tadalafil oral jellies for the 
treatment of erectile dysfunction. The jellies were prepared by using carbopol 940 with 
different concentration as a polymer and propylene glycol as a co-polymer. The prepared 
jellies were evaluated for its various physio-chemical parameters such as pH, appearance, 
viscosity, in vitro drug release. The obtained result to form physio-chemical parameters 
complies with standard the in vitro drug release so highest percentage immediate limit release 
with increased concentration carbopol 940 (F5) this present studies concluded that tadalafil 
oral jellies alternative dosage for oral dispersible tablets and drug could produce improved 
bioavailability and compared to other fast releasing dosage form.   
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                                                       2.  INTRODUCTION 
Erectile dysfunction (ED) is the most common sexual problem in men1. ED is defined 
as a difficulty in initiating or maintaining penile erection adequate for sexual activity. ED has 
a weighty effect on intimate relationships, quality of life, and overall self-esteem for men. In 
addition, ED may also be an early indication of undetected cardiovascular disease.One of the 
largest current studies of ED, Male Aging Study, established that the prevalence of ED 
increases with age as it affects up to half of the male population between 40 and 70 years old. 
Thus, as the world’s older population increases, it is estimated that the prevalence of ED will 
double from 152 million men in 1995 to 322 million men in 2025, indicating a dire need to 
reevaluate current ED therapeutic strategies. In most documented cases, ED may also present 
with comorbidities of hypertension, diabetes mellitus, obesity, and atherosclerosis.2   
During the 1980s, most of the pioneering research in ED was sparked by the 
introduction of intracavernosal vasoactive drugs, which were very effective as agents 
inducing penile rigidity.It was not until the late 1990’s and early 2000’s that oral 
phosphodiesterase-5 inhibitors were introduced, which were truly instrumental in 
revolutionizing the sexual medicine field. Currently   Erectile dysfunction (ED) is treated 
with PDE5 inhibitors, lodenafil, sildenafil, tadalafil,udenafil, vardenafil, avanafil 
andtrazodone. The first line treatment of erectile dysfunction consists of a trial of PDE5 
inhibitor drugs (the first of which was sildenafil or Viagra). They are available as tablet 
dosage forms commercially.How evertadalafil being poorly soluble may pose dissolution 
absorbtion problem resulting in poor bioavailabilty of   the drug there for difficulty to 
currently  erectiledysfunction. 3 
Tadalafil is used to treat erectile dysfunction in men and it is a selective inhibitor of 
cyclicguanosine monophosphate (cGMP)and specific phosphodiesterase type5(PDE 5)  
Chemically, tadalafil is pyrazino [1’, 2’: 1,6] pyrido [3,4-b] indole-1, 4-dione, 6-(1,3- 
benzodioxon–5-yl)–2,3,6,7,12,12a-hexahydro- methyl- (6R, 12aR).  It is not official in any of 
the pharmacopoeia.Tadalafil is a PDE5 inhibitor, currently marketed in pill form for treating 
erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the 
treatment of pulmonary arterial hypertension. The approved dose for pulmonary arterial 
hypertension is 40 mg (two 20-mg tablets) once daily. Tadalafil is also manufactured and 
sold under the name of Tadacip by the Indian pharmaceutical company Cipla in doses of 
10mg and 20 mg.Pharmacologic distinction is its longer half-life (17.50 hours) – compared to 
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Viagra (4.0–5.0 hours) and Levitra (4.0–5.0 hours) – resulting in longer duration of action, 
and so partly responsible for “The Weekend Pill” sobriquet.4 
Furthermore, the longer half-life is the basis for current investigation of tadalafil's 
daily therapeutic use in relieving pulmonary arterial hypertension. Currently, sildenafil (trade 
name Revatio) is approved in several world regions as a thrice-daily therapy for pulmonary 
arterial hypertension. Penile erection during sexual stimulation is caused by increased penile 
blood flow resulting from the relaxation of penile arteries and the smooth muscle of the 
corpus cavernosum. This response is mediated by the release of nitric oxide (NO) from nerve 
terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle 
cells. Cyclic GMP relaxes smooth muscle and increases blood flow to the corpus caver 
nosum. The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by 
increasing the amount of cGMP. Tadalafil,sildenafil and vardenafil inhibits PDE5.5  
However, because sexual stimulation is required to initiate the local penile release of 
nitric oxide, tadalafil's inhibition of PDE5 will have no effect without direct sexual 
stimulation of the penis. The recommended tadalafil starting dose for most men is 10 mg, 
taken as needed before sexual activity (but not more than once daily).The dose may be 
increased to 20 mg or decreased to 5 mg, per its efficacy and the man's personal tolerance of 
the drug. To avoid the inconvenience of a man having to program and plan using tadalafil 
around the time of his anticipated sexual activity, In patients with pulmonary arterial 
hypertension, the pulmonary vascular lumen is decreased as a result of vasoconstriction and 
vascular remodeling, resulting in increased pulmonary artery pressure and pulmonary 
vascular resistance. Jellies are transparent, opaque, non-greasy semisolid gels generally 
applied externally. They are used for medication, lubrication and some miscellaneous 
application. Gelling agent used normally are tragacanth, sodium alginate, pectin, starch, 
gelatin, cellulose derivative like hydroxy propyl methyl cellulose (HPMC), methyl cellulose 
(MC), carbomer, polyvinyl pyrrolidone.6 
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2. REVIEW OF THE LITERATURE                            
Erectile dysfunction (ED, impotence) and premature ejaculation (PE) are the two 
main complaints in male sexual medicine. New oral therapies have completely changed the 
diagnostic and therapeutic approach to ED and the guidelines office of the European 
Association of Urology (EAU) has appointed an expert panel to update previously published 
EAU guidelines for ED or impotence. Erectile dysfunction (ED) is defined as the consistent 
or recurrent inability of a man to attain and/or maintain penile erection sufficiently for a 
sexual activity. A 3-month minimum duration is accepted for the establishment of the 
diagnosis. Several studies have provided data on the prevalence of ED. The prevalence of ED 
on a worldwide basis has a great deal of variation around 9%-69%. And, there is a clear 
increase of this disorder at older ages. In all studies, ED has a rather high rate from 20% to 
40% for the ages 60 to 69 years old, some increasing after the age of 65 years old.  
Erectile Dysfunction (ED) or male impotence is defined as the inability to develop or maintai
n an erection sufficienfor satisfactory sexual performance.7 
Epidemiology of Erectile dysfunction 
Erectile dysfunction is a significant and common medical problem. Recent 
epidemiologic studies suggest that approximately 10% of men aged 40-70 have severe or 
complete erectile dysfunction, defined as the total inability to achieve or maintain erections 
sufficient for sexual performance. An additional 25% of men in this age category have 
moderate or intermittent erectile difficulties. The disorder is highly age-dependent, as the 
combined prevalence of moderate to complete erectile dysfunction rises from approximately 
22% at age 40 to 49% by age 70. Although less common in younger men, erectile 
dysfunction still affects 5%-10% of men below the age of 40. Findings from these studies 
show that erectile dysfunction impacts significantly on mood state, interpersonal functioning, 
and overall quality of life.8 
Erectile dysfunction is strongly related to both physical and psychological health. 
Among the major risk factors are diabetes mellitus, heart disease, and hypertension and 
decreased HDL levels. Medications for diabetes, hypertension, cardiovascular disease and 
depression may also cause erectile difficulties. In addition, there is a higher prevalence of 
erectile dysfunction among men who have undergone radiation or surgery for prostate cancer, 
or who have a lower spinal cord injury or other neurological diseases (e.g. Parkinson’s 
disease, multiple sclerosis). Life style factors, including smoking, alcohol consumption and 
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sedentary behavior are additional risk factors. The psychological correlates of erectile 
dysfunction include anxiety, depression and anger. Despite its increasing prevalence among 
older men, erectile dysfunction is not considered a normal or inevitable part of the aging 
process. It is rarely (in fewer than 5% of cases) due to aging-related hypogonadism, although 
the relationship between erectile dysfunction and age-related declines in androgen remains 
controversial.9 
Erectile impairment is a condition with profound   psychological consequences and 
may interfere with a man’s overall well-being, self-esteem and interpersonal relationships. 
Conservative estimates of its incidence have been made at between 10-20 million men. 
Furthermore, it has been shown that erectile problems account for 400,000 out-patient 
physician visits, 30,000 hospital admissions and an annual financial outlay by our health 
industry of 146 million dollars. Kinsey’s report in 1948 was the first study to address the 
occurrence of sexual dysfunction in the general population. Results from this study, based on 
the detailed interview of 12,000 males, stratified for age, education and occupation, indicated 
an increasing rate of impotence with age. Its prevalence was cited as less than 1% in men 
under 19 years of age, 3% of men under 45 years, 7% less than 55 years and 25% by the age 
of 75 years. In 1979, Gerhard reanalyzed the Kinsey data and in a chart of over five thousand 
men, 42% admitted to erectile difficulties. As the number of vascular risk factors (such as, 
cigarette smoking, hypertension, cardiac disease, hyperlipidemia, and diabetes) increases so 
too does the likelihood of erectile dysfunction. This finding was confirmed in Virago’s 
analysis of 400 impotent men, demonstrating that 80% of these men had physiologic 
abnormalities and that vascular risk factors were more common in this group compared to the 
general population. 
While androgens are essential to the growth and differentiation of the male genital 
tract, the development of secondary sexual characteristics and the presence of libido their role 
in the erectile process remains unclear. At this time, the nature of an appropriate hormonal 
investigation, whether a complete hormone panel is required for every patient or whether a 
single testosterone determination constitute effective screening remains debated. Indeed, 
disagreement exists on whether free or total testosterone levels are more important in he 
evaluation of the impotent male. Nevertheless, endocrinopathies probably account for up 
between 3-6% of all organic erectile dysfunction and those  endocrinopathies that may lead to 
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impotence include hypogonadism, hypothyroidism, hyperthyroidism, hyperprolactinemia, 
diabetes mellitus, adrenal disorders, chronic liver disease, chronic renal failure and AIDS.10 
Drug associated erectile dysfunction is common and the list of medications that can 
induce erectile dysfunction is significant. Medication-induced impotence has been estimated 
occurring in up to 25% of patients in a medical outpatient clinic. Antihypertensive agents are 
associated with erectile difficulties, depending upon the specific agents in 4-40% of patients. 
They induce impotence either by actions at the central level (clonidine), by direct actions at 
the corporal level (calcium channel blockers) or by purely dropping systemic blood pressure 
upon which the patient has relied to maintain an intracorporal pressure sufficient for the 
development of penile rigidity. 
Several medications cause impotence based on their anti-androgen actions, for 
example estrogens, LHRH agonists, H2 antagonists, and spironolactone. Digoxin induces 
erectile difficulties via blockade of the NA-K-ATP as pump resulting in a net increase in 
intracellular Ca and subsequent increased tone in the caporal smooth muscle. The 
psychotropic medications alter CNS mechanisms. Chronic use of recreational drugs has been 
associated with erectile dysfunction. Other agents affect erection through, as of yet, unknown 
mechanisms. Ultimately, it is essential to define a mechanism for each medication suspected 
of causing impotence. Furthermore, the diagnosis of drug-induced erectile dysfunction must 
be predicated upon reproducibility of the problem with medication administration and 
cessation of the problem upon its discontinuation. Apart from the factors already outlined 
(vascular risk factors, endocrinopthies and psychological problems) that may lead to 
impotence the following conditions may induce erectile problems. Renal Failure: Up to 40% 
of men suffering from chronic renal failure have some form of erectile dysfunction.11  
The mechanism by which impotence results in this disorder is probably multifactorial, 
involvingendocrinologichypogonadism, hyperprolactinemia; neuropathicdiabetes induced 
nephropathy and vascular factors. Hatzichristou investigated the vascular etiologies in a 
cohort of men with chronic renal failure who had undergone hemodynamic evaluation and 
found an inordinately high incidence of corporovenoclusive dysfunction. The role of renal 
transplantation in the development of erectile dysfunction in these patients is variable. In 
some, transplant improves the renal function to the point where the patients’ erectile function 
also improves and in others, particularly those men who had received 2 transplants, the 
erectile function may deteriorate further. 
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Neurologic disorders: Neurogenic erectile dysfunction may be caused by disorders 
such as, stroke, brain and spinal tumors, cerebral infection, Alzheimer’s disease, temporal 
lobe epilepsy and multiple sclerosis (MS). Agarwal cited a 85% incidence of impotence in a 
group of men following stroke, while Goldstein noted 71% of men with MS were affected by 
erectile difficulties. More recently, it has beenn recognized that AIDS has associated with an 
autonomic neuropathy which may cause neurogenic erectile dysfunction.Pulmonary diseases: 
Fletcher noted a 30% incidence of impotence in men with chronic obstructive pulmonary 
disease (COPD), all of whom had normal peripheral and penile pulses by Doppler 
assessment,suggestingthe COPD was  the primary etiologic factor.Systemic disorders: Apart 
from diseases already mentioned (diabetes, vascular diseases, renal failure) some other 
disorders are associated with impotence. Scleroderma may result in erectile dysfunction as a 
result of the small vessel vasculopathy that it causes. Chronic liver disease has been 
associated with erectile impairment in up to 50% of patients with this disorder. this incidence 
is somewhat dpendent on the etiology of the liver dysfunction, alcoholic liver disease having 
a higher incidence than non-alcoholic.12 
Mechanism Of Erectile Dysfunction 
The word Impotence is derived from the Latin language and literally means loss of 
power. The word is also used to show an inability to do anything about a certain situation. 
Erectile functions is a very complicated process and while getting an erection might appear to 
be simple for most men the mechanisms and functions going on are elaborate and complex. 
The actual structure of the penis for example consists of a number of different components. 
Firstly there are the corpus cavernous which are 2 columns made up of spongy tissue, then 
there is the corpus spongiosum that is a spongy chamber that contains the tube which allows 
urine to flow from the bladder into the penis.The erectile tissue that makes up these structures 
is full of tiny blood vessels known as cavernous sinuses and these blood vessels are covered 
by muscle and elastic fibrous tissue made up of collagen.The mechanism of an erection is 
also dependent on nitric oxide and when a man gets an erection his central nervous system 
allows the release of chemicals, the most important one being nitric oxide. 
The nitric oxide boosts the the manufacture of cyclic GMP which is directly 
responsible for allowing the muscles in the penis to relax. With these muscles relaxed the 
blood can flow into the cavernous sinuses and this fills the penis with blood. When the penis 
is full of blood it will normally be double the it’s previous size. The process also involves the 
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shutting down of the veins around the chambers locking the blood in them and keeping the 
erection hard and rigid. The nitric oxide is an essential part of the erection process and too 
much of it means that you are unable to get rid of your erection. After arousal and ejaculation 
the cyclic GMP has to be got rid of and an so an enzyme known as phosphodiesterase-5 
(PDE5) forms which reacts with the cyclic GMP and removes it. In fact the main erectile 
dysfunction drugs Viagra, Cialis and Levitra are known as PDE-5 inhibitors as they shop the 
formation of the PDE-5 which means that the erection will be sustained.13 
Other factors are also essential for the efficient working of an erection. The right 
balance of the hormone testosterone and oxygen rich blood as well as healthy and unblocked 
arteries are also needed for good erectile function. Psychological factors can also play a part 
on making sure that your erection functions properly. Most men have no idea of the 
complicated issues involved sustaining an erection and are unaware that they need to 
maintain good sexual health in order to keep functioning well sexually. 
Statistics on Male Sexual Dysfunction 
Erectile dysfunction is estimated to effect 150 million men worldwide, and more than 
one million men in Australia. Overall, 25% of Australian men report erectile dysfunction and 
8.5% report severe erectile dysfunction. In one study, 9.6% reported 'occasional' erectile 
dysfunction, 8.9% reported erectile dysfunction occurring 'often', and 18.6% reported erectile 
dysfunction occurring 'all the time'. Of these, only 11.6% had received treatment. In another 
study, only 14.1% of men reported that they had received treatment, despite experiencing 
erectile dysfunction for longer than 12 months.  
Erectile dysfunction is never 'normal', however it does become more common and 
more severe as men age. One Australian study reported the rate of erectile dysfunction in 
different age groups: 
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Due to the ageing Australian population, erectile dysfunction is expected to become 
more common. There is no difference between the prevalence of erectile dysfunction between 
"white-collar" and "blue-collar" workers in Australia.14 
Sexual dysfunction associated with cancer 
Between 10 and 88% of patients diagnosed with cancer experience sexual problems 
following diagnosis and treatment. The prevalence varies according to the location and type 
of cancer, and the treatment modalities used. Sexuality may be affected by chemotherapy, 
alterations in body image due to weight change, hair loss or surgical disfigurement, hormonal 
changes, and cancer treatments that directly affect the pelvic region. Sexual problems are 
reported in many patients with prostate and testicular cancer. They are also reported in 
patients with cancer that does not directly affect sexual organs, including lung cancer (48% of 
patients),Hodgkin's disease (50%),laryngeal (%60) and head and neck cancers (39-
74%).Below are some statistics that you may find helpful to be able to learn more about your 
condition. 
Statistics 
 1 in 10 men in the world are thought to suffer from erectile dysfunction. 
 It is estimated that half of all men who have diabetes suffer from erectile dysfunction. 
 If a man smokes more than 1 packet of cigarettes per day then they have a 50% higher 
chance of erectile problems than a man who is a non-smoker. 
 Men over the age of 75 have a 77.5% chance of suffering from erectile problems. 
 Men between the ages of 20 and 29 only have a 6.5% chance of having erectile 
problems. 
AGE PERCENTAGE 
20-29 9.2 
30-39 8.4 
40-49 13.1 
50-59 33.5 
60-69 51.5 
70-79 69.2 
80+ 76.2 
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 It is thought that erectile dysfunctions cause the breakdown of 20% of all 
relationships. 
 A shocking estimate is that only 33% of men who have erectile dysfunctions seek 
help and advice about their problems. 
 If you have problems with your erections 20% or less of the time then it is unlikely 
that you will need treatment. 
 Over 20 million men all over the world have used or are currently using Viagra to 
treat erectile dysfunction. 
 In 66% of the times that Viagra is taken, men are able to have sexual intercourse. 
 48% of men suffer one or more side effects when using Viagra. 
 Underlying health issues such as diabetes or heart disease account for 70% of all 
erectile dysfunction cases. 
 Psychological causes such as stress and anxiety are estimated to cause around 10 % to 
20% of all erectile dysfunction cases. 
 It is estimated that in 80% of all cases the causes of erectile problems are down to 
physical reasons.15 
ROLE OF TADALAFIL IN ERECTILEDYSFUNCTION:- 
Tadalafil is currently approved in at least 90 countries as an oral treatment for erectile 
dysfunction (ED). It is marketed throughout the world as Cialis1 (pronounced ‘‘See-AL-
is’’).In Saudi Arabia, tadalafil is marketed as bothCialis1 and Snafi1.Tadalafil is an inhibitor 
of PDE5. After entering smooth muscle cells in arteries within the corpus cavernosum of the 
penis, tadalafil competitively inhibits PDE5, and prevents the inactivation of the intracellular 
messenger cGMP. Consequently, by inhibiting PDE5 in the corpus cavernosum, tadalafil 
prolongs the action of cGMP, facilitating the erectile response to sexual stimulation. 
Supplement.16 
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APPROACHES TO IMPROVE THE TADALAFIL (RELATED WORKS) 
 
Vikrant Vyas et al., 17 (2009) Dissolution behaviour of a poorly water-soluble drug, 
tadalafil, from its solid dispersion systems with poloxamer 407 has been investigated. Solid 
dispersion systems of tadalafil were prepared with poloxamer 407 in 1:0.5, 1:1.5 and 1:2.5 
ratios using the melting method. Characterization of binary systems with FTIR and XRPD 
studies demonstrated the presence of strong hydrogen bonding interactions, a significant 
decrease in crystalline and the possibility of existence of amorphous entities of the drug. In 
the binary systems tested, 1:0.5 proportion of tadalafil/poloxamer 407 showed rapid 
dissolution of tadalafil (DE30 70.9 ± 3.6 %). In contrast, higher proportions of poloxamer 
407 (1:1.5 and 1:2.5) offered no advantage towards dissolution enhancement of the drug, 
indicating altered rheological characteristics of the polymer at its higher concentration, which 
might have retarded the release rate of tadalafil. 
 
N. Kannappan et al 18 (2010) in the present study simple, reliable and reproducible 
HPLC methods were developed for the analysis of Tadalafil and Sildednafil citrate (API). 
The column used was YMC-Pack ODS AQ (150 mm x 4.6 mm,i.d.).The mobile phase used 
was phosphate buffer (10mM, pH 3.0) acetonitrile gradient run at the flow rate of 1mL/min 
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with UV (PDA) detector at 220nm at ambient temperature. Extraction of Tadalafil and 
Sildenafil citrate from tablet was carried out using methanol. Linearity was observed in the 
range from 50 to 150µg/ml for tadalafil with a correlation coefficient (R2) 0.99 and 10ng/ml 
as the limit of detection. The values of linearity range, correlation coefficient (R2) and limit 
of detection were 50 to 150µg/ml, 0.99 and 20ng/ml respectively for sildenafil. Parameters of 
validation prove the precision and stability of the method and it’s applicability for the Assay 
of tadalafil and sildenafil citrate. The method is suitable for routine analysis of the drug. 
 
V. Ravi Kumar et al 19 (2012) in the present study to enhancement of oral 
bioavailability of poorly water-soluble drugs remains one of the most challenging aspects of 
drug development. Tadalafil a BCS class II drug is an impotence agent. It is indicated for the 
treatment of erectile dysfunction and is a selective inhibitor of cyclic guanosine 
monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE-5).However, insolubility 
and poor dissolution of this molecule, delays its rate of absorption and finally the onset of 
action. Solid dispersion has been successfully utilized as dissolution enhancement technique 
using water soluble polymers for wide variety of poorly water-soluble drugs. The present 
study aims at enhancement of dissolution profile of Tadalafil using PVP K30 and PEG 6000 
as carriers by solid dispersion technique. Solid dispersion containing Tadalafil was further 
investigated by drug content, in-vitro drug release, FTIR, DSC, XPRD and SEM analysis. 
Absence of significant drug‐carrier interaction was confirmed by IR and DSC data. XPRD 
reveals that crystallinity nature of Tadalafil was decreased. From the study it was concluded 
that the in-vitro dissolution of Tadalafil can be enhanced by solid dispersion technique. 
 
T. VaniPrasanna et al 20 (2012) in the present studyTadalafil (TD), a PDE-5 
inhibitor, belongs to BCS class II. It is poorly soluble in water and requires enhancement in 
solubility and dissolution rate for increasing its oral bioavailability. In the present 
investigation, solid dispersed systems of tadalafil with poloxamer188 and sodium starch 
glycolate were prepared using solvent evaporation technique. The dissolution rate of the drug 
and poloxamer188 based solid dispersion was significantly higher than the sodium starch 
glycolate (SSG) based preparations and pure drug which reaches closer to the dissolution 
profile of marketed product. This was due to an increase in surface area of drug available for 
dissolution. Characterization of binary systems with FTIR studies demonstrated the presence 
of strong hydrogen bonding interactions, a significant decrease in crystallinity and the 
possibility of existence of amorphous entities of the drug. In the binary systems tested, 1:0.5 
 Page 
13 
 
  
proportion of Tadalafil/poloxamer188 showed rapid dissolution of tadalafil (DE30 56.68 %). 
In the binary systems, tested (1:0.5) proportion of tadalafil/poloxamer188 showed rapid 
dissolution of tadalafil. In contrast, higher proportion of polaxmer188 (1:1) offered no 
advantage towards dissolution enhancement of the drug, indicating altered rheological 
characters of the polymer at its higher concentration, which might have retard the release rate 
of tadalafil. The tablets were prepared for the optimized formula of solid dispersion, by wet 
granulation technique. The solid dispersion tablets were evaluated and compared with 
tadalafil marketed product. 
 
K.MallikarjunaRao et al 21 (2012) in the present study Fast dissolving tablets are 
solid tablets and designed to dissolve/disintegrate in the patient’s mouth within few seconds 
or minutes, without the need to drink or chew Tadalafil. The Main aim of the present study 
was prepare fast dissolving tablets of Tadalafil in the oral cavity with enhanced dissolution 
rate. The fast dissolving tablets of zidovudine was prepared with different concentrations of 
ingredients such as SSG and crosspovidone as superdisintegrants and ß-Cyclodextrin as a 
solubilizing agent by using direct compression technique. The prepared tablets were 
evaluated for the different evaluation parameters such as angle of repose, compressible index, 
hausner’s ratio, percentage of drug content, hardness, thickness, friability, In-Vitro 
disintegration, In-Vitro dissolution and stability studies. The evaluation parameters of the 
prepared formulations results were obtained the satisfactory results. From the all the 
formulations, formulation (ODTT-VIII) was found to be the best formulations, based upon 
the In-Vitro drug release studies  
 
Gudipati Edukondalu et al 22  (2012) in the present study simple, precise and 
accurate RP-HPLC method was developed and validated for rapid assay of Tadalafil tablet 
dosage form. Isocratic elution at a flow rate of 1.3ml/min was employed on a 
symmetryChromosil C18 (250x4.6mm, 5µm in particle size) at ambient temperature. The 
mobile phase consisted of Methanol: Acetonitrile 65:35 v/v. The UV detection wavelength 
was 222 nm and 20µl sample was injected. The retention time for Tadalafil was 7.8 min. The 
percentage RSD for precision and accuracy of the method was found to be less than 2%. The 
method was validated as per the ICH guidelines. The method was successfully applied for 
routine analysis of Tadalafil tablet dosage form and bulk drug. 
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Sabry kh. Mohamed*et al 23 (2013) in the present study Ion – associate complexes of 
sildenafil, tadalafil and vardenafil hydrochlorides with [Manganese (II) and Cobalt (II)] 
thiocyanates, potassium ferricyanide, sodium cobaltinitrite and ammonium reineckate were 
precipitated and the excess unreacted metal complex was determined. A new method using 
atomic emission and atomic absorption spectrometry for the determination of the above drugs 
in pure solutions, in pharmaceutical preparations and urine of diabetic patient’s type 2 was 
given. The drugs can be determined by the affort method in the ranges 0.56 - 104.28, 0.64 - 
117.81 and 0.63 – 115.39 µg mL-1 solutions of Sd, Td and Vd, respectively. 
 
Vinesha et al 24 (2013) co-crystallization is an emerging method to optimize 
physicochemical properties of pharmaceutically active compounds including dissolution rate 
and stability. The main aim of this study was to increase the solubility by co crystal approach 
and characteristic the co-crystal (1:1) involving tadalafil and salicylic acid which were 
prepared by solvent evaporation method. The prepared co-crystals showed increase solubility 
than pure drug. 
 Wasfy M. Obeidat et al  25  (2013) The aim of this work was to prepare and evaluate 
Tadalafilnanosuspensions and their PEG 4000 solid dispersion matrices to enhance its 
dissolution rate. Nanosuspensions were prepared by precipitation/ultrasonication technique at 
5°C where different stabilizers were screened for stabilization. Nanosuspensions were 
characterized in terms of particle size and charge. Screening process limited suitable 
stabilizers into structurally related surfactants composed of a mixture of Tween80 and 
Span80 at 1:1 ratio (in percent, weight/volume) in adjusted alkaline pH (named TDTSp-OH). 
The surfactant mixture aided the production of nanosuspensions with an average particle size 
of 193 ± 8 nm and with short-term stability sufficient for further processing. Solid dispersion 
matrices made of dried Tadalafil nanosuspensions or dried Tadalafil raw powder suspensions 
and PEG 4000 as a carrier were prepared by direct compression. Drying was performed via 
dry heat or via freeze dry. Drug release studies showed that, in general, tablet formulations 
made of freeze-dried product exhibited faster initial release rates than the corresponding 
tablets made of oven-dried products which could be attributed to possible larger crystal 
growth and larger crushing strengths of oven-dried formulations. At best, 60% of drug was 
released from solid dispersion matrices, while more than 90% of drug was released from 
TDTSp-OH nanosuspension within the first 5 min. In conclusion, tadalafil nanosuspensions 
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obtained using a mixed surfactant system provided rapid dissolution rates of Tadalafil that 
can theoretically enhance its bioavailability. 
M.shanker et al 26 (2013)  in the present study simple, selective, precise and stability 
indicating RP-HPLC method for the determination of tadalafil was developed and validated 
in oral jelly dosage forms. The chromatographic parameters comprised of Zorbax C18 
column (250X4.6 mm, 5µ) and mixture of buffer: acetonitrile (55: 45 v/v) as mobile phase. 
The detection was observed at 225nm with 1.5 ml/min flow rate. The developed method has 
been validated according to ICH and USP guidelines. The linearity studies showed a good 
correlation over the range of 10 to 75 µg/ml with correlation coefficient (r2) of 0.998. The 
drug was subjected to forced degradation analysis on varied conditions of acidic, basic, 
peroxide, thermal, light and UV radiation. All the results have proved that the method was 
selective and reproducible for the determination of tadalafil. The proposed stability indicating 
RP-HPLC method can be effectively employed for the determination of tadalafil in routine 
drug analysis of oral jelly dosage forms 
 
REALETED WORKS ON ORAL JELLY:- 
D.K Jain* et al 27 (2008) In the present study Convenience of administration and 
patient compliance are gaining significant importance in the design of dosage forms. 
Metformin hydrochloride and Glimepiride is orally administered antihyperglycemic agent, 
used in the management of non-insulin-dependent (type-2) diabetes mellitus. Difficulty in 
swallowing (dysphagia) is common among all age groups, especially in elderly and 
pediatrics. Unfortunately, a high percentage of patients suffering from type-2 diabetes are 
elderly people showing dysphagia. Persons suffering from dysphagia may get choked when 
they consume liquid formulation, thus to alleviate such problem liquid formulation of high 
viscosity was prepared. Formulation of oral soft jellies was carried out using combination of 
hydrophilic polymers guar gum and pectin. 3 different concentrations of guar gum (0.3 to 
0.5% w/v) and 2 concentration of pectin were used (0.2 to 0.3% w/v) respectively. The 
prepared batches were evaluated for appearance, viscosity, pH, drug content, syneresis, in 
vitro drug release, and taste masking. The batch with 0.5% w/v guar gum and 0.2% pectin not 
only showed 80% drug release at 60 min, but all the desired organoleptic properties. The taste 
masking was carried out using non nutritive sugar and flavors. The optimized batch showed 
substantial stability when subjected to short term stability study (0-8°C and Room 
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temperature). The problem of dose measurement by patients was outweighed as oral 
medicated gels are to be packed in unit dose container. 
Deborah Evangeline.D et al 28 (2011) In the present study medicated jelly with 
Ajowan extract was formulated using polymers like sodium alginate and tragacanth. The 
jellies were evaluated for their physiochemical parameters like pH, spreadability and stability 
studies. The antimicrobial activities of the gels were also carried out. Formulations using 
sodium alginate shows desired properties and significant antimicrobial activity.  Ajowan is 
the dried ripe seed of Trachysperumammi (L), Sprague, belonging to the family Apiaceous .It 
has an agreeable taste and an aromatic odour. It is valued for its antiseptic, antispasmodic, 
stimulant, tonic and carminative properties. It is also effective in treating sore throat, 
bronchitis, diarrhoea and Cholera .Therefore, the present study was carried out to formulate a 
medicated jelly with ajowan extract by using different gelling agents like sodium alginate and 
tragcanth in various proportions. The jellies thus prepared were evaluated for their 
appearance, pH, spreadability, antimicrobial activity and also for its stability studies. 
 
Thejomoorthy et al 29 (2012) In the present study analytical method based on Liquid-
liquid extraction has been developed and validated for analysis of Tadalafilin rat plasma. 
Tadalafil-D3 was used as an internal standard. Zorbax-SB C18, 75 x 4.6 mm, 3.5 µm column 
provided chromatographic separation of analyte followed by detection with mass 
spectrometry. The method involves simple isocratic chromatographic condition and mass 
spectrometric detection in the positive ionization mode using an API-4200 system. The total 
run time was 3.0 minutes. The proposed method has been validated with linear range of 0.50–
1000.00 ng/mL for Tadalafil. The intra-run and inter-run precision values are within 1.37 - 
2.25% and 2.23- 5.31%. The overall recovery for Tadalafil and Tadalafil-D3 was 91.07% and 
86.66%. This validated method was applied successfully in rat plasma samples for 
pharmacokinetic study. 
Tanu Godhwani1 et al 30 (2012)  In the  present study was conducted with an aim to 
formulate and evaluate the unit molded jelly containing calcium supplement and optimization 
of this dosage form which will dissolve slowly when kept in contact with mouth without any 
irritation or inflammation and bitter after taste. The oral route of administration is the 
preferred route of drug delivery. Now-a-days, jelly candies have become very common in 
children as they enjoy chewing the jelly. The formulation of jelly is advantageous for drug 
delivery in pediatric patients and may also be used in the cases where tablet or capsule 
swallowing is difficult. The jellies were evaluated for their physiochemical parameters like 
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Color, taste loss on drying, pH, spreadability, test for presence of heavy metals and stability 
studies. All the ten formulation (F1 to F10) under study was found to be stable and showed 
comparable appearance, pH, spreadability and viscosity. The article describes about the 
formulation aspect of jelly, excipients and flavors employed and the evaluation parameters 
along with the drug used in the formulation. The optimized formulation F4 was found to be 
stable for the period of 3 months as per ICH guidelines. 
C.D.Nieuwoudt et al 31 (2012) Pharmacokinetics and Stability of an Enrofloxacin 
Oral Gel Formulation in Horses. Enrofloxacin, in an oral flavored gel formation, achieves 
clinically effective serum concentrations necessary to treat susceptible infections in horses. 
The formulated gel retains full potency for a 3-mo period. Oral antibiotic choices to treat 
infections in horses are limited. In many cases, such as peritonitis, osteomyelitis, or pleura 
pneumonia, to name a few, long-term therapy may be necessary. In instances where owners 
need to administer the antibiotic doses, the IV or IM route may be difficult or dangerous, and 
the oral route is preferable. Enrofloxacin is not only another alternative to the few antibiotics 
currently available to give orally to treat infections in horses, but also offers a broad spectrum 
of activity. The commercial enrofloxacin tablets, approved for use in dogs, are cumbersome 
to crush, and the volume of the cattle injection is large, resulting in loss of some of the dose 
when administered. We developed an oral flavoured gel formulation from the cattle injection 
that significantly eased administration of the dose. The purpose of this study was to 
determine whether enrofloxacin achieves clinically sufficient serum concentrations after oral 
administration of the gel formulation. In addition, the stability of the extemporaneous 
formulation was studied. 
T. Salunke et al 32 (2013)In the  Present study was aimed to formulate and evaluate 
medicated Jelly of Bitter drugs i.e. Ofloxacin and Ornidazole. For taste masking of 
Ofloxacin, ion-exchange resin method was used. The resins like Indion 204, Indion 214 and 
Tulsion 335 was tested at various ratios. Based on the results Tulsion 335 with the ratio 1:1.5 
was selected for complexation. For taste masking of Ornidazole, addition of sweetening agent 
method was used. The slurry was prepared using Sorbitol 70%, Polyethylene glycol 400 and 
Glycerin in the concentration of 10%, 6% and 7% respectively. It was observed that the batch 
F7 containing 0.4% Xanthan gum, 0.5% Carrageenan and 0.3% sodium citrate and shows 
satisfactory results. The optimized formulation F7 evaluated which shows satisfactory results. 
pH of the maximum stability of Ofloxacin and Ornidazole in aqueous phase is in between 5 
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to 6. The drug content of jelly of batches F1 to F9 was evaluated by HPLC method. The 
results are between 97.00% to 103.00% for Ofloxacin and 95.00 % to 104.00 for Ornidazole. 
The dissolution studies of the Medicated jelly for all the formulations show more than 70% 
drug release at 20 minutes time point and complete drug release within 45 minutes. The 
optimized formulation F7 kept for the three month at storage condition and it was evaluated 
with similar test as per initial analysis which shows satisfactory results. 
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4. AIM AND OBJECTIVE OF THE STUDY 
The present aimed to formulate and evaluate comparison tadalafil oral jellies for 
erectile dysfunction with marketed product. 
OBJECTIVES OF THE STUDY: 
 Preparation of standard curve 
 Formulation of tadalafil oral medicated jelly by using simple mixing.  
 Characterization of the prepared medicated jellies for its odour, taste, pH, viscosity, 
drug content and invitro drug release. 
 Stability studies for best formulations. 
 Release Kinetics. 
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5. PLAN OF WORK 
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Tadalafil 
           Class   : 
IUPAC Name : 
   
Molecular formula : 
Molecular weight : 
Structure  :   
  
Melting point  :   
Half-life  :  
Protein binding :   
Solubility                  :   
Route   :   
           Adverse reactions    : 
     
 Excretion              :  
 
6.1 DRUG PROFILE 
Phosphodiesterase type 5 inhibitor [33] 
(6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a
hexahydro- 2-methyl-pyrazino [1', 2':1,6]  
pyrido[3,4- b]indole-1,4-dione 
C22H19N3O4  
389.404 g/mol 
          
 301-3020 C 
17.5hrs 
  94% 
Practically insoluble in water & very slightly soluble
in   ethanol 
Oral 
Dyspepsia, Back pain, Myalgia, Nasalcongestion,   
Flushing, Pain in limb   
  Urine > 30%,Feces> 60% 
 
-   
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Mechanism of Action 
Penile erection during sexual stimulation is caused by increased penile blood flow 
resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This 
response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial 
cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes 
smooth muscle relaxation and increased blood flow into the corpus cavernosum. The 
inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the 
amount of cGMP. Tadalafil inhibits PDE5. Because sexual stimulation is required to initiate 
the local release of nitric oxide, the inhibition of PDE5 by tadalafil has no effect in the 
absence of sexual stimulation. Studies in vitro have demonstrated that tadalafil is a selective 
inhibitor of PDE5. PDE5 is found in corpus cavernosum smooth muscle, vascular and 
visceral smooth muscle, skeletal muscle, platelets, kidney, lung, cerebellum, and pancreas. In 
vitro studies have shown that the effect of tadalafil is more potent on PDE5 than on other 
phosphodiesterases. 
Pharmacodynamics  
Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial 
hypertension (PAH). Part of the physiological process of erection involves the release of 
nitric oxide(NO) in the corpus cavernosum. This then activities the enzyme quanylatecyclase 
which result in increased levels of cyclic guanosine monophosphate (cGMP), leading to 
smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood 
and an erection. Tadalafil is a potent and selective inhibitor of cGMP specific 
phosphodiestrase type 5(PDE5) which is responsible for degradation of cGMP in the corpus 
cavernosum. This means that with tadalafil on board, normal sexual stimulation leads to 
increased level of cGMP in the corpus cavernosum which leads to better erections. Without 
sexual stimulation and no activation of the NO/cGMP system the tadalafil should not causes 
an erection. 
Pharmacokinetics 
Over a dose range of 2.5 to 20 mg, tadalafil exposure (AUC) increases proportionally 
with dose in healthy subjects. Steady-state plasma concentrations are attained within 5 days 
of once-daily dosing, and exposure is approximately 1.6-fold greater than after a single dose. 
Tadalafil is eliminated predominantly by hepatic metabolism, mainly by cytochrome P450 
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3A4 (CYP3A4). The concomitant use of potent CYP3A4 inhibitors such as ritonavir or 
ketoconazole resulted in significant increases in tadalafil AUC values. 
Absorption  
 After single oral-dose administration, the maximum observed plasma concentration 
(Cmax) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). 
Absolute bioavailability of tadalafil following oral dosing has not been determined. The rate 
and extent of absorption of tadalafil are not influenced by food; thus CIALIS may be taken 
with or without food.  
 Distribution  
 The mean apparent volume of distribution following oral administration is 
approximately 63 L, indicating that tadalafil is distributed into tissues. At therapeutic 
concentrations, 94% of tadalafil in plasma is bound to proteins. Less than 0.0005% of the 
administered dose appeared in the semen of healthy subjects.  
Metabolism  
Tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite. The 
catechol metabolite undergoes extensive methylation and glucuronidation to form the 
methylcatechol and methylcatecholglucuronide conjugate, respectively. The major circulating 
metabolite is the methylcatecholglucuronide. Methylcatechol concentrations are less than 
10% of glucuronide concentrations. In vitro data suggests that metabolites are not expected to 
be pharmacologically active at observed metabolite concentrations. 
 Elimination  
 The mean oral clearance for tadalafil is 2.5 L/hr and the mean terminal half-life is 
17.5 hours in healthy subjects. Tadalafil is excreted predominantly as metabolites, mainly in 
the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 
36% of the dose) 
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      6.2 EXCIPIENTS PROFILE 
SORBITOL 
 Nonproprietary Names BP  :  Sorbitol JP: D-Sorbitol PhEur:  
Sorbitol USP-NF: Sorbitol 
 Synonym    :  C*PharmSorbidex; E420; 1, 2, 3,4,5,6 
     hexanehexol; Liponic 70- NC; 
Liponic 76-NC; Meritol; Neosorb;  
Chemical Name and 
    CAS Registry Number  : D-Glucitol [50-70-4] 
 
 Empirical Formula    : C6H14O6    
 Molecular Weight   : 182.17. 
 
 Structural Formula   :  
                                     
 
Functional Category   : Humectant; plasticizer; stabilizing agent; 
  Sweetening agent; tablet and capsule diluent. 
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 Applications in pharmaceutical formulation or technology 
  Sorbitol is widely used as an excipient in pharmaceutical formulations. It is also used 
extensively in cosmetics and food products. Sorbitol is used as a diluent in tablet 
formulations prepared by either wet granulation or direct compression. Sorbitol has been used 
as a plasticizer in film formulations. sorbitol is used as a vehicle in sugar-free formulations 
and as a stabilizer for drug.It has also been shown to be a suitable carrier to enhance the in 
vitro dissolution rate of indometacin. In syrups it is effective in preventing crystallization 
around the cap of bottles. Sorbitol is additionally used in injectable and topical preparations, 
and therapeutically as an osmotic laxative. Sorbitol may also be used analytically as a marker 
for assessing liver blood flow. 
 Description 
  Sorbitol is D-glucitol. It is a hexahydric alcohol related to mannose and is isomeric 
with mannitol. Sorbitol occurs as an odorless, white or almost colorless, crystalline, 
hygroscopic powder. Four crystalline polymorphs and one amorphous form of sorbitol have 
been identified that have slightlydifferentphysicalproperties,e.g.meltingpoint.Sorbitolis 
available in a wide range of grades and polymorphic forms, such as granules, flakes, or 
pellets that tend to cake less than the powdered form and have more desirable compression 
characteristics. Sorbitol has a pleasant, cooling, sweet taste andhasapproximately50–60% of 
the sweetness of sucrose. 
 Stability and storage conditions 
Sorbitol is chemically relatively inert and is compatible with most excipients. It is 
stable in air in the absence of catalysts and in cold, dilute acids and alkalis. Sorbitol does not 
darken or decompose at elevated temperatures or in the presence of amines. It is non-
flammable, noncorrosive, and non-volatile. Although sorbitol is resistant to fermentation by 
many micro- organisms, a preservative should be added to sorbitol solutions. Solutions may 
be stored in glass, plastic, aluminium, and stainless steel containers. Solutions for injection 
may be sterilized by autoclaving. The bulk material is hygroscopic and should be stored in an 
airtight container in a cool, dry place. 
\ 
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 Incompatibilities 
Sorbitol will form water-soluble chelates with many divalent and trivalent metal ions 
in strongly acidic and alkaline conditions. Addition of liquid polyethylene glycols to sorbitol 
solution, with vigorous agitation, produces a waxy, water-soluble gel with a melting point of 
35–408C. Sorbitol solutions also react with iron oxide to become discolored. Sorbitol 
increases the degradation rate of penicillin’s in neutral and aqueous solutions. 
 Method of manufacture 
 Sorbitol occurs naturally in the ripe berries of many trees and plants.It was first 
isolated in1872fromtheberries of theMountain Ash (Sorbusamericana). Industrially, sorbitol 
is prepared by high-pressure hydrogenation with a copper–chromium or nickel catalyst, or by 
electrolytic reduction of glucose and corn syrup. If cane or beet sugars are used as a source, 
the disaccharide is hydrolyzed to dextrose and fructose prior to hydrogenation. 
 Safety 
Sorbitol is widely used in a number of pharmaceutical products and occurs naturally 
in many edible fruits and berries. It is absorbed more slowly from the gastrointestinal tract 
than sucrose and is metabolized in the liver to fructose and glucose. Its caloric value is 
approximately 16.7J/g (4cal/g).  
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PROPYLENE GLYCOL 
Nonproprietary Names BP   :  Propylene Glycol JP: Propylene Glycol PhEur:
      Propylene Glycol USP: Propylene Glycol 
 Synonyms      : 1,2Dihydroxypropane; E1520; 2hydroxy 
propanol; methyl ethyl- ene glycol; methyl 
glycol; propane-1,2-diol; propylenglycolum. 
 Chemical Name and  :  1, 2-Propanediol [57-55-6] ()-1, 2-Propanediol 
    CAS Registry Number              [4254-14-2] (þ)-1, 2-Propanediol [4254-15-3] 4 
Empirical Formula    : C3H8O2 
 Molecular Weight    : 76.09 
 Structural Formula           :  
 
 Functional category  
Antimicrobial preservative; disinfectant; humectant; plasticizer; solvent; stabilizing 
agent; water-miscible cosolvent. 
 Applications in pharmaceutical formulation or technology  
Propylene glycol has become widely used as a solvent, extractant, and preservative in 
a variety of parenteral and nonparenteral pharmaceutical formulations. It is a better general 
solvent than glycerin and dissolves a wide variety of materials, such as corticosteroids, 
phenols, sulfa drugs, barbiturates, vitamins (A and D), most alkaloids, and many local 
anesthetics. As an antiseptic it is similar to ethanol, and against molds it is similar to glycerin 
and only slightly less effective than ethanol. Propylene glycol is commonly used as a 
plasticizer in aqueous film-coating formulations. Propylene glycol is also used in cosmetics 
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and in the food industry as a carrier for emulsifiers and as a vehicle for flavours in preference 
to ethanol, since its lack of volatility provides a more uniform flavour.  
Description  
Propylene glycol is a clear, colourless, viscous, practically odourless liquid, with a 
sweet, slightly acrid taste resembling that of glycerine. 
 Stability and storage conditions 
At cool temperatures, propylene glycol is stable in a well-closed container, but at high 
temperatures, in the open, it tendstooxidize,givingrise to products such as propionaldehyde, 
lactic acid, pyruvic acid, and acetic acid. Propylene glycol is chemically stable when mixed 
with ethanol (95%), glycerine, or water; aqueous solutions may be sterilized by autoclaving. 
Propylene glycol is hygroscopic and should be stored in a well- closed container, protected 
from light, in a cool, dry place. 
 Incompatibilities 
Propylene glycol is incompatible with oxidizing reagents such as potassium 
permanganate. 
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TRIETHANOLAMINE 
Nonproprietary Names BP  : TriethanolaminePhEur:Trolamine 
USP-NF: Trolamine 
 Synonyms    : TEA;Tealan; trihydroxytriethylamine;  
tris (hydroxyethyl)amine; trolaminum. 
 Chemical Names and   : 2, 20,200-Nitrilotriethanol [102-71-6] 
 Empirical Formula    : C6H15NO3 
 Molecular Weight    : 149.19 
 
 Structural Formula   : 
      
 
Functional category   : Alkalizing agent, emulsifying agent. 
 Applications in pharmaceutical formulation or technology 
Tri ethanolamine is widely used in topical pharmaceutical formulations, primarily in 
the formation of emulsions. When mixed in equimolar proportions with a fatty acid, such as 
stearic acid or oleic acid, triethanolamine forms an anionic soap with a pH of about8, which 
may be used as an emulsifying agent to produce fine-grained, stable oil-in-water emulsions. 
Concentrations that are typically used for emulsification are 2–4% v/v of tri ethanolamine 
and 2–5 times that of fatty acids. In the case of mineral oils, 5% v/v of triethanolamine will 
be needed, with an appropriate increase in the amount of fatty acid used. Preparations that 
contain triethanolamine soaps tend to darken on storage. However, discoloration may be 
reduced by avoiding exposure to light and contact with metals and metal ions. 
Triethanolamine is also used in salt formation for injectable solutions and in topical analgesic 
 Page 
30 
 
  
preparations. It is also used in sun screen preparations.(1) Triethanolamine is used as an 
intermediate in the manufacturing of surfactants, textile specialties, waxes, polishes, 
herbicides, petroleum demulsifies, toilet goods, cement additives, and cutting oils. 
Triethanolamine is also claimed to be used for the production of lubricants for the rubber 
gloves and textile industries. Other general uses are as buffers, solvents, and polymer 
plasticizers, and as a humectants. 
 Description 
Triethanolamine is a clear, colourless to pale yellow-colour viscous liquid having 
slight ammonia Caldor. It is a mixture of bases, mainly 2, 20,200-nitrilotriethanol, although it 
also contains 2, 20- iminobisethanol (diethanolamine) and smaller amounts of 2- 
aminoethanol (monoethanolamine). 
 Stability and storage conditions  
Triethanolamine may turn brown on exposure to air and light. The 85% grade of 
triethanolamine tends to stratify below 158C; homogeneity can be restored by warming and 
mixing before use. Triethanolamine should be stored in an airtight container protected from 
light, in a cool, dry place. See Mono ethanolamine for further information. 
 Incompatibilities  
Triethanolamine is tertiary amine that contains hydroxyl groups. it is capable of 
undergoing reactions typical of tertiary amines and alcohols. Triethanolamine will react with 
mineral acids to form crystalline salts and esters. With the higher fatty acids, triethanolamine 
forms salts that are soluble in water and have characteristics of soaps. Triethanolamine will 
also react with copper to form complex salts. Discoloration and precipitation can take place 
in the presence of heavy metal chloride to replace the hydroxyl groups with halogens. The 
products of these reactions are very toxic, resembling other nitrogen mustards’ salts.  
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 SUCRALOSE:- 
Non proprietary Names   :    Sucralose 
Synonyms    :    Splenda; sucralosa; sucralosum;  
Chemical Name              :    1, 6 - Dichloro-1, 6 - dideoxy –  
 b- D - fructofuranosy l - 4- chloro  
 4 –  deoxya – D - galactopyranoside 
Empirical Formula  :  C12H19Cl3O8 
Molecular Weight   :           397.64  
Structural formula  :   
      
Functional Category  :  Sweetening agent. 
Description   : Sucralose is a white to  
Off-white colored, free-flowing,  
Crystalline powder. 
Stability and storage conditions    
Sucralose is a relatively stable material. In aqueous solution, athighly acidic 
conditions (pH < 3), and at high temperatures (4358C), it is hydrolyzed to a limited extent, 
producing 4-chloro-4-deoxygalactose and 1,6-dichloro-1,6-di deoxyfructose. In food 
products, sucralose remains stable throughout extended storage periods, even at low pH. 
However, it is most stable at pH 5–6. Sucralose should be stored in a well-closed container in 
a cool, dry place, at a temperature not exceeding 218C. Sucralose, when heated at elevated 
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temperatures, may break down with the release of carbon dioxide, carbon monoxide, and 
minor amounts of hydrogen chloride. 
Applications in pharmaceutical formulation or technology  
Sucralose is used as a sweetening agent in beverages, foods, and pharmaceutical 
applications. It has a sweetening power approximately 300–1000 times that of sucrose and 
has no aftertaste. It has nonutritional value, is noncariogenic, does not promote dental caries, 
and produces no glycemic response. 
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6.3. POLYMER PROFILE 
CARBOPOL 940 
Synonym                         :    Acritamer, Acrylic acid polymer,  Carbopol, Carboxy vinyl    
                                              Polymer. 
Non proprietary names :    B.P: carbomer U.S.P carbomeri 
Chemical name               : Carboxypolymethelene.    
 Structure                        : 
                                                                                                                
 
Molecular weight :  Carbomer resins are theoretically  
Estimated at 7x105 to 4x109. 
Category  :  Emulsifying agent, suspending agent,  
tablet binder, viscosity- enhancing agent. 
Description   :  Carbomers are white coloured, fully,  
Acidic, hygroscopic power with slightly characteristic 
odour. 
Solubility :  Soluble in water, and after neutralization,  
in ethanol (95%) and glycerine. 
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Viscosity   :  29,000-39,000 cps (0.5%w/v),  
Carbomers disperse in water to form acidic colloidal 
solutions of low. Viscosity when neutralized products 
highly viscous gels. 
Stability and storage   
Carbomers are stable, through hygroscopic materials and can be heated at 
temperatures below 104ºC for up to 2 hours without affecting their thickening efficacy. Dry 
powder forms of carbomers do not support the growth of moulds and fungi but aqueous 
dispersions are very susceptible to micro-organisms.  
Safety 
Carbomers are regulated as nontoxic and non-irritant material. 
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7. MATERIALS AND INSTRUMENTS 
`    MATERIALS  
 
S.NO 
 
MATERIALS 
 
 
SOURCE 
 
USES 
 
1 
 
Tadalafil 
 
Sai mirra Inno pharm pvt ltd, 
Chennai. 
 
Active 
pharmaceutical 
ingredient 
 
 
2 
 
Sorbitol 
 
Keshavhi chem pvt ltd 
 
Stabilizing agent 
 
 
3 
 
Propylene glycol 
 
Prime laboratories pvt.ltd chennai 
 
Polymer 
 
 
4 
 
Triethanolamine 
 
AES manufacturing pvt,ltd 
chennai 
 
Emulzifying agent 
 
 
5 
 
Carbopal 
 
Alpha chemical pvt ltd  chennai 
 
Gel forming agent 
 
 
6 
 
Surcolose 
 
Lowkal healthcare pvt ltd 
bengaluru 
 
Sweetening agent 
 
 
7 
 
Sunset yellow 
 
Sai mirra inno pharma pvt ltd 
chennai 
 
Flavoring & coloring 
agent 
 
 
8 
 
Orange flavor 
 
Sai mirra inno pharmap vt ltd 
chennai 
 
Flavoring  agent 
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EQUIPMENTS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO INSTRUMENTS SOURCE 
1 Electronic weighing balance Percisa 205A. 
2 Magnetic stirrer Lasco. 
3 pH meter Elchem. 
4 Viscosity Viscometer 
5 Dissolution test apparatus Electro Lab dissolution 
apparatus. 
6 UV-Spectrophotometry Shimadzu. 
7 FT-IR IR Affinity-1, Shimadzu. 
8 Sonicator Saisonic Ultrasonic 
agitator. 
9 HPLC LC-2010 AHT, Shimadzu. 
10 Stability chamber InlabEquipments. 
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                                                       8. METHODLOGY 
8.1 PREFORMULATION STUDIES 
COMPATIBILITY STUDIES 
Infra red spectra matching approach was used for the detection of any possible chemical 
reaction between the drug and the excipients. A physical mixture (1:1) of drug and polymer 
was prepared and mixed with suitable quantity of potassium bromide. About 100mg of this 
mixture was compressed to form a transparent pellet using a hydraulic press at 2 tons 
pressure. It was scanned from 4000 to 150 cm-1 in FT-IR spectrophotometer. The IR 
spectrum of the physical mixture was compared with those of pure drug and excipients and 
matching was done to detect any appearance of disappearance of peaks. 
FORMULATION OF JELLY 
 Propylene glycol to be warmed well. 
 Tadalafil should be added to the above solution until the drug gets dissolved and cool 
it at room temperature. 
 Carbopal 940 sieved at 100 # mesh and triethanolamine added and kept it for 30 mins 
and looks like jelly. 
 Sucrulose dissolved in DM water and mixed to the jelly. 
 Finally colouring and flavouring agents were added. 
 This formulation was carried out with different formulation F1 –F6 whose quantity 
are given in the tabular column. 
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Formula 
Table: 1 
 
Ingredients 
 
F1 
 (mg) 
 
F2 
(mg) 
 
F3 
(mg) 
 
F4 
(mg) 
 
F5 
(mg) 
 
F6 
(mg) 
 
Tadalafil 
 
20 
 
20 
  
 20 
 
20 
 
20 
 
20 
 
Sorbital 
 
2200 
 
2200 
 
2200 
 
2200 
 
2200 
 
2200 
 
Propylene glycol 
 
2715 
 
2712.5 
 
2710 
 
2707.5 
 
2705 
 
2702.5 
 
Carbapol 940 
 
5 
 
7.5 
 
10 
 
12.5 
 
15 
 
17.5 
 
Triethanolamine 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
Sucrolose 
 
30 
 
30 
 
30 
 
30 
 
30 
 
30 
 
Orange flavor 
 
1ml 
 
1ml 
 
1ml 
 
1ml 
 
1ml 
 
1ml 
 
sunset yellow 
 
1ml 
 
1ml 
 
1ml 
 
1ml 
 
1ml 
 
1ml 
 
Total 
 
5000 mg 
 
5000 mg 
 
5000 mg 
 
5000 mg 
 
5000 mg 
 
5000 mg 
 
Evaluation of prepared oral jelly  
Appearance   
The prepared jelly was inspected visually for clarity, color and presence of any 
particulate materials. The test is important regarding patient compliance and acceptance.   
Determination of pH  
The pH values (Table 2) of 1% aqueous solutions of the prepared jellies were checked 
by using a calibrated digital pH meter (Elico India) at constant temperature. For the purpose 
1g of the weighed formulation was dispersed in 100 ml of distilled water and the pH was 
noted. The standard pH of the jelly was 7.5-8.1.   
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Determination of Viscosity  
Viscosity of the jelly was carried out by using (LV) Brookfield viscometer (Dial 
type). As the system is non-Newtonian spindle no. 4 was used. Viscosity was measured for 
the fixed time 2 min at 1.5rpm. Viscosity determination of jelly was done by Brookfield 
viscometer (Dial type).  
Factor = 4 M  
M = 1000  
Viscosity = Dial reading x factor  
The viscosity was calculated by following relation. 
Viscosity in centipoises = Dial reading × Factor  
The factor in above relation is found in factor finding chart provided by manufacturer of 
Brookfield viscometer. 
DISSOLUTION              
 
Apparatus : USP Apparatus II (paddle) 
Medium : 1000 mL of 0.5% SLS in water 
RPM  : 100 
Temperature : 37°C ± 0.5°C 
Time  : 45 minutes 
Standard Preparation 
Weigh accurately 20 mg standard of Tadalafil into a 100 mL volumetric flask. 
Dissolve in 10 mL Acetonitrile and dilute to volume with Acetonitrile and mix. Transfer 5 
mL of this solution into a 100 mL volumetric flask and dilute to volume with dissolution 
medium and mix. 
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Sample preparation 
Each jar containing 5gm of samplein 1000 mL dissolution medium that has been 
equilibrated to 37°C ± 0.5°C. Take care to exclude air bubbles from  the  surface  of  the  
tablets,  start  the  apparatus  immediately. Collect the sample after 45 minutes. Withdraw 
sample from a zone midway between the surface of the medium and top of the rotating blade 
and not less than 1 cm from the vessel wall  and filter  through Whatman No.1filter paper by 
discarding first 5 mL. Transfer 5 mL of this solution into a 10 mL volumetric flask and dilute 
to volume with dissolution medium and mix. 
Procedure 
Measure the absorbance of standard and sample preparations at 285 nm using 
dissolution medium  as blank. 
Calculation 
Test Abs.     SW      5         1000      10     
% Label claim of Tadalafil dissolved =     ------------ x  ------ x -----  x   ------   x -----   x   P         
                                                               Std Abs.   100     100         20          5          
Where, 
SW =   Standard weight taken in mg 
P =    (%) Purity of Tadalafil Working Reference Standard  
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DRUG CONTENT ESTIMATION BY HPLC METHOD 
Chromatographic conditions 
Mobile phase: Buffer: Acetonitrile (70: 30)  
[Buffer : Acetate Buffer pH 2.8 - Dissolve 4  g of anhydrous Sodium Acetate in about 
840  ml of water, add sufficient Glacial Acetic Acid to adjust the pH to 2.8 (about 155  ml) 
and dilute to 1000  ml with water.] 
Column: C18, 250 x 4.6 mm (NucleodurC18, 5µm is suitable) 
Flow rate: 1.2 ml/min 
Wave length: 283 nm 
Temperature: Ambient 
Load: 20 µl 
Diluent: Water: Acetonitrile (1:1) 
Standard preparation: Weigh accurately 20 mg of Tadalafil WRS into a 100 mL volumetric 
flask. Dissolve and dilute to volume with diluent. 
Sample preparation: Weigh accurately5gm of sample (equivalent to about 20 mg of 
Tadalafil) into a 100 mL volumetric flask. Add 30 mL of diluent and sonicate for 30 minutes. 
Cool and dilute to volume with diluent. Mix well. Filter through 0.45 µ membrane filter by 
discarding the first 5 mL. 
Procedure: Separately inject 6 replicate injections of standard preparation and the sample 
preparation into the liquid chromatography and record the peak area for major peaks.  
System suitability: The relative standard deviation of six injections of standard preparation 
is not more than 2%. The tailing factor of Tadalafil peak is not more than 2.0. 
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Calculation: Calculate the content of Tadalafil present per tablet using the formula :  
                      Test Area      Std. Wt.                                     100          purity 
Assay    =                        X                 X  Dil.factor   X                   X               X    Avg Wt. 
                        Std.Area        100                                         Test Wt.        100 
 
Where, 
Sw = Weight of Tadalafil working reference standard taken in mg 
Tw = Test weight taken in g 
Av.wt. = Average weight in g 
P = (%) Purity of Tadalafil working reference Standard 
Stability Studies at Various Temperatures   
Stability studies of prepared jelly at different temperature condition were carried out 
with regards to temperature 4oC, 45oC and at room temperature. The stability studies are 
carried out for 3 months and the formulations were analyzed for the changes in the physical 
parameters like appearance, pH, viscosity, sugar crystallization and stiffness at 15 days, 30 
days, 60 days and 90 days. 
KINETIC ANALYSIS OF IN -VITRO RELEASE RATES OF FORMULATIONS 
 The results of in-vitro release profile obtained for all the formulations were plotted in 
modes of data treatment as follows 
Zero-order kinetic model-cumulative percentage drug release versus time Korsmeyer’s 
equation/peppa's model-log cumulative percentage drug released versus log 
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1. Zero-order kinetics 
          Zero order release would be predicted by the following equation:- 
At = A0 - K0 t 
Where, 
                 At = Drug release at time‘t’ 
                 A0 = Initial drug concentration 
                 K0 = Zero order rate constant (hr-1) 
          When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys zero-order release kinetics, with a slope equal to K0. 
2. First- order kinetics 
          First-order release would be predicted by the following equation:- 
Log C = log C0 - Kt /2.303 
 Where, 
                C=Amount of drug remained at time‘t’ 
                C0=Initial amount of drug 
                K=First-order rate constant (hr-1 
 When the data is plotted as log cumulative percent drug remaining versus time yields 
a straight line, indicating that the release follow first order kinetics. The constant K can be 
obtained by multiplying 2.303 with slope values. 
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3. Higuchi's model 
         Drug release from the matrix devices by diffusion has been described by following 
Higuchi's classical diffusion equation. 
Q = [Dε /τ(2A - εCs) Cst]1/2 
  Where, 
              Q=Amount of drug released at time‘t’ 
              D=Diffusion coefficient of drug in the matrix 
              A=Total amount of drug in unit volume of matrix 
              Cs= The solubility of drug in the matrix 
              ε= Porosity of the matrix 
              τ= Tortuosity 
               t= Time (hrs) at which Q amount of drug is released 
          Above equation may be simplified if one assumes that D, Cs, and A, are constant. Then 
equation becomes: 
Q = K t ½ 
  When the data is plotted according to equation i.e. cumulative drug release versus 
square root of time yields a straight line, indicating that the drug was released by diffusion 
mechanism. The slope is equal to 'K'. 
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4. Korsmeyer’s equation/ peppa's model                         
 To study the mechanism of drug release from the solid dispersions, the release data 
were also fitted to the well-known exponential equation (Korsmeyer’s equation/peppa's law 
equation), which is often used to describe the drug release behavior from polymeric systems. 
Mt/Ma = Ktn 
 Where, 
Mt/Ma = The fraction of drug released at time‘t’ 
K= Constant incorporating the structural and geometrical characteristics of  the 
drug/polymeric 
N= Diffusion exponent related to the mechanism of release 
Above equation can be simplified by applying log on both sides, and we get: 
Log Mt/Ma = Log K +n Log t 
          When the data is plotted as log of drug released versus log time, yields a straight line 
with a slope equal to 'n' and the 'K' can be obtained from y-intercept. For Fickian release 
'n'=0.5 while for anomalous (non-Fickian) transport 'n' ranges from 0.5 to 1.0 as shown 
below. 
        Table: 2 Mechanism of drug release as per korsemeyer equation/peppa's model 
S.No n Value Drug release 
1. n < 0.5 Fickian release 
2. 0.5<n<1 Non- Fickian release 
3. n>1 Case II transport 
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9.RESULTS 
Tadalafil oral jellies were prepared and evaluated to increase its local action and 
bioavailability. In the present study 6 formulations with variable concentration of polymer 
were prepared and evaluated for it physio -chemical, in-vitro drug release studies. 
PREFORMULATION STUDIES 
COMPATIBILITY STUDIES [FTIR] 
Compatibility studies were performed using FTIR spectrophotometer. The IR 
spectrum of pure drug and polymer were studied. The characteristic absorption peaks of 
Tadalafil were obtained at the peaks obtained in the spectra of each formulation correlates 
with the peaks of drug spectrum. That indicates the drug was compatible with the excipients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak Wave length cm-1 
N - H Stretching 3387.11 
C - H Stretching 2970.48 
C = O Stretching 1716.70 
C = C Stretching 1452.45 
N - CH3 Stretching 2300.01 
TADALAFIL STANDARD 
 
- FTIR 
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CARBOPOL – 940P STANDARD - FTIR 
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SUCRALOSE STANDARD - FTIR 
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TADALAFIL + CARBOPOL 940P - FTIR 
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TADALAFIL + SUCRALOSE - FTIR 
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Physical properties of the oral jelly formulations   
Table: 3 
Formulations Appearance pH Taste Viscosity 
(cps)* 
F1 Transparent 7.5 Bitter 273600 
F2 Transparent 7.6 Bitter 351234 
F3 Opaque 7.0 Bitter 542335 
F4 Opaque 7.6 Bitter 335435 
F5 Opaque 8.1 Bitter 294520 
F6 Transparent 7.7 Bitter 482355 
  
STANDARD CALIBRATION CURVE OF TADALAFIL 
 Standard calibration curve of tadalafil was determined by plotting absorbance vs 
concentration at 285nm and it follows the beers law. the results were show in table 
CONCENTRATION ABSORBANCE 
1 2 0.18 
2 4 0.36 
3 6 0.55 
4 8 0.72 
5 10 0.89 
6 12 1.1 
 
 
DISSOLUTION STUDIES 
FORMULATION 1 
y = 0.090x
R² = 0.999
0
0.5
1
1.5
0 2 4 6 8 10 12 14A
B
S
O
R
B
A
N
C
E
CONCENDRATION
STANDARD CALIBARATION CURVE OF 
TADALAFIL
 Page 
53 
 
  
PERCENTAGE OF DRUG RELEASE 
Table: 4 
 
IN-VITRO DRUG RELEASE STUDIES FOR FORMULATION F1 
                
 
KINETICS OF DRUG RELEASE: 
Table: 5 
0
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PERCENTAGE OF DRUG RELEASE
% DRUG RELEASE
S. 
No 
Times 
in 
(mins) 
Absorbance 
     (nm) 
concentration  Amount 
of drug 
release 
(mg) 
Amount 
of drug 
release 
mg/1000 
Cumulative  
of % drug 
release  
% drug 
release 
1 10 0.215 1.17 0.011 11.7 11.72 59.50% 
2 15 0.217 1.18 0.11 11.8 11.83 60% 
3 20 0.225 1.22 0.12 12.2 12.26 62.2% 
4 30 0.230 1.25 0.12 12.5 12.53 63.6% 
5 45 0.234 1.27 0.12 12.7 12.75 64.7% 
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y = 0.167x + 57.77
R² = 0.947
58
59
60
61
62
63
64
65
66
0 10 20 30 40 50
%
 D
R
U
G
 R
E
LE
A
S
E
TIME (MIN)
ZERO ORDER RELEASE
ZERO ORDER
Linear (ZERO ORDER)
S.NO Time 
in 
Mins 
Square root 
 of time 
log time % drug 
release 
log % 
drug 
release  
% drug 
remaini
ng 
Log % 
drug 
remaining 
1 10 3.162 1 59 1.770 41 1.612 
2 15 3.872 1.17 60.1 1.778 39.9 1.600 
3 20 4.47 1.30 62.4 1.795 37.6 1.575 
4 30 5.47 1.47 63.5 1.802 36.5 1.562 
5 45 6.70 1.65 65.1 1.810 34.9 1.542 
 Page 
55 
 
  
              
 
               
 
 
 
 
 
 
 
y = -0.002x + 1.623
R² = 0.949
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FORMULATION 2 
y = 0.067x + 1.698
R² = 0.926
1.76
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Table: 6 
 
\ 
 
 
 
KINETICS OF DRUG RELEASE: 
Table: 7 
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PERCENTAGE DRUG PROFILE
PERCENTAGE DRUG 
PROFILE
S.NO Times 
in 
(mins) 
Absorbance 
     (nm) 
concentration  Amount 
of drug 
release 
(mg) 
Amount 
of drug 
release 
mg/1000 
Cumulative  
of % drug 
release  
% drug 
release 
1 10 0.236 1.318 0.013 13.18 13.19 66.99 
2 15 0.242 1.351 0.013 13.51 13.53 68.6 
3 20 0.245 1.368 0.013 13.68 13.70 69.5 
4 30 0.248 1.386 0.013 13.85 13.86 70.3 
5 45 0.253 1.413 0.014 14.13 14.14 71.8 
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y = 0.129x + 65.84
R² = 0.854
65
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ZERO ORDER  RELEASE
zero order plot
Linear (zero order plot)
S.NO Time 
in 
Mins 
Square root 
 of time 
log time % drug 
release 
log % 
drug 
release  
% drug 
remaining 
Log % 
drug 
remaining 
1 10 3.163 1.12 66.9 1.819 34 1.53 
2 15 3.87 1.17 68.6 1.83 32 1.50 
3 20 4.47 1.30 69.5 1.83 31 1.49 
4 30 5.47 1.47 70.3 1.84 30 1.47 
5 45 6.47 1.65 71.8 1.85 28.2 1.45 
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y = -0.002x + 1.538
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y = 0.061x + 1.750
R² = 0.902
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FORMULATION 3 
Table: 8 
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PERCENTAGE DRUG 
RELEASE
S.NO Times 
in 
(mins) 
Absorbance 
     (nm) 
concentration  Amount 
of drug 
release 
(mg) 
Amount 
of drug 
release 
mg/1000 
Cumulative  
of % drug 
release  
% 
drug 
release 
1 10 0.254 1.383 0.013 13.83 13.34 70.29 
2 15 0.259 1.41 0.014 14.10 14.12 71.63 
3 20 0.262 1.42 0.014 14.27 14.28 72.50 
4 30 0.266 1.44 0.014 14.48 14.56 73.61 
5 45 0.271 1.47 0.014 14.76 14.75 75.0 
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KINETICS OF DRUG RELEASE: 
Table: 9 
 
 
       
        
 
 
 
y = 0.134x + 69.67
R² = 0.836
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Linear (ZERO ORDER )
S.NO Time 
in 
Mins 
Square root 
 of time 
log time % drug 
release 
log % 
drug 
release  
% drug 
remaining 
Log % 
drug 
remaining 
1 10 3.162 1 70.2 1.846 29.8 1.474 
2 15 3.87 1.17 71.5 1.854 28.5 1.484 
3 20 4.47 1.30 73.2 1.864 26.8 1.428 
4 30 5.47 1.47 74.6 1.872 25.4 1.404 
5 45 6.70 1.65 75 1.875 25 1.397 
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FORMULATION 4 
Table: 10 
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KINETICS OF DRUG RELEASE: 
Table: 11 
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     (nm) 
concentration  Amount 
of drug 
release 
(mg) 
Amount 
of drug 
release 
mg/1000 
Cumulative  
of % drug 
release  
% drug 
release 
1 10 0.275 1.497 0.014 14.97 14.99 76.1 
2 15 0.279 1.51 0.015 15.19 15.21 77.2 
3 20 0.283 1.54 0.015 15.41 15.42 78.3 
4 30 0.286 1.55 0.015 15.57 15.59 79.1 
5 45 0.293 1.59 0.015 15.95 15.97 81.0 
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y = 0.132x + 75.13
R² = 0.981
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 of time 
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release 
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drug 
release  
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remaining 
Log % 
drug 
remaining 
1 10 3.16 1 76.2 1.88 23.8 1.376 
2 15 3.87 1.17 77.1 1.88 22.9 1.359 
3 20 4.47 1.30 78.2 1.89 21.8 1.338 
4 30 5.47 1.47 79.1 1.89 20.9 1.320 
5 45 6.47 1.65 81 1.90 19 1.278 
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FORMULATION 5 
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KINETICS OF DRUG RELEASE: 
Table: 13 
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     (nm) 
concentration  Amount of 
drug 
release 
(mg) 
Amount 
of drug 
release 
mg/1000 
Cumulative  
of % drug 
release  
% 
drug 
release 
1 10 0.301 1.639 0.016 16.39 16.41 83.3 
2 15 0.310 1.688 0.016 16.84 16.90 85.7 
3 20 0.325 1.77 0.017 17.70 17.71 89.9 
4 30 0.329 1.79 0.017 17.91 17.93 91.0 
5 45 0.345 1.87 0.018 18.79 18.80 95.4 
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y = 0.327x + 81.19
R² = 0.927
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Log % 
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remaini
ng 
1 10 3.162 1 83.3 1.92 16.7 1.22 
2 15 3.87 1.17 85.7 1.93 14.3 1.15 
3 20 4.47 1.30 89.9 1.95 10.1 1.0 
4 30 5.47 1.47 91.0 1.95 9 0.95 
5 45 6.47 1.65 95.4 1.97 4.6 0.66 
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FORMULATION 6 
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KINETICS OF DRUG RELEASE: 
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concentration  Amount 
of drug 
release 
(mg) 
Amount 
of drug 
release 
mg/1000 
Cumulative  
of % drug 
release  
% drug 
release 
1 10 0.279 1.522 0.015 15.22 15.24 77.38 
2 15 0.296 1.61 0.016 16.1 16.14 81.9 
3 20 0.318 1.73 0.017 17.32 17.33 88.0 
4 30 0.329 1.79 0.017 17.91 17.93 91.1 
5 45 0.339 1.84 0.018 18.46 18.48 93.8 
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Square root 
 of time 
log time % drug 
release 
log % 
drug 
release  
% drug 
remaining 
Log % drug 
remaining 
1 10 3.162 1 77.3 1.88 22.62 1.354 
2 15 3.87 1.17 81.9 1.91 18.03 1.255 
3 20 4.47 1.30 88 1.94 12 1.07 
4 30 5.47 1.47 91.1 1.95 8.95 0.95 
5 45 6.47 1.65 93.8 1.97 6.2 0.79 
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MARKETED PRODUCT 
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KINETICS OF DRUG RELEASE: 
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     (nm) 
concentration  Amount 
of drug 
release 
(mg) 
Amount 
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release 
mg/1000 
Cumulative  
of % drug 
release  
% 
drug 
release 
1 10 0.307 1.67 0.016 16.72 16.74 84.96 
2 15 0.315 1.71 0.017 17.15 17.17 87.1 
3 20 0.345 1.87 0.018 18.80 18.82 95.4 
4 30 0.347 1.88 0.018 18.91 18.93 96.0 
5 45 0.355 1.93 0.019 19.35 19.36 98.2+ 
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Log % 
drug 
remaining 
1 10 3.162 1 84.9 1.924 16 1.204 
2 15 3.87 1.17 87.1 1.939 13 1.113 
3 20 4.47 1.30 95.48 1.977 5 0.698 
4 30 5.47 1.47 96.0 1.982 4 0.602 
5 45 6.47 1.65 98.24 1.991 2 0.301 
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COMPARATIVE STUDY INVITRO DRUG RELEASE PROFILE OF TADALAFIL 
ORAL JELLY 
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SIMILARITY FACTORS 
Comparative studies with marketed Product 
Table: 18 
Time F1 F2 F3 F4 F5 F6 MP 
0 0 0 0 0 0 0 0 
10 59.5 65.5 70.2 76.1 83.3 77.3 84.9 
15 60 68.6 71.6 77.2 85.7 81.9 87.1 
20 62.2 69.5 72.5 78.2 89.9 88 95.6 
30 63.6 70.2 73.6 79.1 91.1 91 96 
45 64.7 71.8 75 81 95.4 93 98.2 
F2 
value 
50.64 56.72 61.80 70.93 93.58 86.30 ------ 
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Cumulative data of release of kinetics (F1 TO F6) 
Table: 19 
 
 
 
 
 
 
 
F.Code Zero 
order 
plot 
First 
order 
plot 
Higuchi 
plot 
Korsemeyer peppas 
plot 
Possible mechanism 
of drug release 
R2 R2 R2 R2 n 
F1 0.947 0.949 0.984 0.926 0.067 Fickian release 
F2 0..854 0.909 0.930 0.902 0.061 Fickian release 
F3 0.836 0.85 0.903 0.997 0.062 Fickian release 
F4 0.981 0.985 0.992 0.957 0.030 Fickian release 
F5 0.927 0.968 0.957 0.971 0.052 Fickian release 
F6 0.849 0.934 0.913 0.951 0.134 Fickian release 
MP 0.925 0.932 0.956 0.808 0.413 Fickian release 
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DRUG CONTENT ESTIMATION:-
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PERCENTAGE OF DRUG RELEASE 
Table: 20 
S. No Formulation 
% Drug Release 
TADALAFIL 
1 M P 99.6 
2 F1 72.34 
3 F2 70.25 
4 F3 70.63 
5 F4 81.63 
6 F5 98.8 
7 F6 95.23 
 
STABILITY STUDIES 
Physical And Chemical Parameters Of Optimized Formulation F5 After 1st, 2nd And 3rd 
Month At20 -250 
Table: 21 
Parameter Initial After 1
st
  
month 
After 2nd 
month 
After 3rd month 
Appearance 
Transparent,opaque,milky 
white 
Semisolid jelly 
No change No 
change 
No change 
Ph 8.0 7.9 8.0 8.1 
Viscosity 
(dyne sec/cm^2) 
294520 294520 294520 294520 
Temp 0c 25 25 25 25 
Drug content of 
tadalafil (%) 
98 98 98 98 
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10. DISCUSSION 
  The results of the present study demonstrated that delivery of tadalafil oral jelly could 
be beneficial to improve the solubility as well as bioavailability of tadalafil. Tadalafil 
recommend in therapy of erectile dysfunction and available as tablets form. Owing to poor 
bioavailability of tadalafil may not control the erectile dysfunction effectively. Focusing on 
this in the present study an attempt was made to develop oral jelly of tadalafil using carbopol 
940 with different concentration as a jelling agent. In FTIR spectra there is no disappearance 
of peak present in drug and physical mixture it shows the compatibility of drug and polymer. 
 The result of physico-chemical parameter such as pH, appearance and viscosity 
shown all formulation were within standard limit and compare to other F5 is considered as 
best in their characteristics. Invitro dissolution study results of  all was formulations shows 
immediate release and it varied according to the concentration of carbopol 940.The 
percentage release of drug increased from 64.75% to 95.4% at higher concentration of 
polymer. The observed result complies with marketed product this f5 is considered as a best 
formulation. 
 The result of drug content estimation show &concentration of drug was higher in f5 
this indicates the influence of polymer. When increasing the concentration of polymer the 
alteration between the polymer and drug will be increased thus increasing concentration of 
drug in dosage form.F2valuesof all formulation and marketed product were 50.64, 56.72, 
61.80, 70.93, 93.58, 86.30 respectively and these results shows all formulations are suitable 
for immediate release dosage form. The observed results were fitted with release kinetics and 
it shows all the formulation obeys first order release with fickaian mechanism. 
 Stability study was performed for the best formulation and the result indicates that the 
prepared jelly was highly stable during its storage. Thus it was concluded among the all 
formulation f5 having better release characteristics due to the higher concentration of 
carbopol 940 and which complies with the results obtained from the marketed product and it 
could be beneficial to improve the bioavailability of tadalafil.          
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11. CONCLUSION 
The present study reveals that tadalafil oral jelly released the drug as rapidly manner 
with improved bioavailability. The observed results were found that the concentration of 
carbopol 940 can influenced the release rate & other physico chemical properties. Thus it can 
be concluded that tadalafil jellies are beneficial in improving the bioavailability of drug as 
compared to other oral fast releasing dosage forms. 
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